Use of TG02 for treating gliomas in pediatric subjects
The present disclosure relates to uses of TG02, for treating a glioma in a pediatric human subject. In certain embodiments, the glioma can be a pediatric high-grade glioma (PHGG), e.g., a diffuse intrinsic pontine glioma (DIPG), and/or a H3.3-mutated glioma (e.g., a H3K27M-mutated glioma). The present disclosure further provides pharmaceutical compositions and kits that include an ERK5 inhibitor.
1. A method for treating diffuse intrinsic pontine glioma (DIPG) in a pediatric human subject, comprising administering to the subject a therapeutically effective amount of (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]-heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (TG02), or a pharmaceutically acceptable salt thereof, in combination with radiation therapy, wherein the DIPG is a H3K27M-mutant DIPG.
2. The method of claim 1 , wherein the TG02 is a citric salt of TG02.
3. The method of claim 2 , wherein the citric salt of TG02 has a powder x-ray diffraction pattern with peaks at 15.2, 15.5, 21.7, 22.1, 23.0, 26.2, and 29.9 degrees 2θ.
4. The method of claim 1 , wherein the pediatric human subject is between about 4 years old and about 11 years old.
5. The method of claim 1 , wherein the TG02 is administered orally in an amount of between about 20 mg and about 100 mg per day.
6. The method of claim 1 , wherein the TG02 is administered intermittently to the pediatric human subject.
7. The method of claim 1 , wherein the radiation is administered to the pediatric human subject in fractionated doses.
8. The method of claim 7 , wherein a total dose of between about 54 Gy and about 60 Gy of the radiation is administered to the pediatric human subject over a period of between about 1 week and about 8 weeks.
9. The method of claim 1 , wherein when the TG02 is administered on the same day as the radiation, and the TG02 is administered between about 1 hour and about 8 hours prior to the administration of the radiation.